BRIEF published on 02/20/2026 at 07:05, 7 months 8 days ago Le rapport annuel 2025 de BB Biotech met en lumière d'importants résultats financiers. Rapport Annuel BB Biotech Valeur Du Portefeuille Rendements Pour Les Actionnaires Gains Financiers
BRIEF published on 02/20/2026 at 07:05, 7 months 8 days ago BB Biotech's 2025 Annual Report Highlights Strong Financial Gains Annual Report Portfolio Value Shareholder Returns BB Biotech Financial Gains
PRESS RELEASE published on 02/20/2026 at 07:00, 7 months 8 days ago EQS-Adhoc: BB Biotech AG publishes its 2025 annual report BB Biotech AG releases its 2025 annual report, reporting a strong performance with a +34.2% total return in CHF. The annual report includes detailed information on the biotechnology sector and the company's investments Financial Results Investment BB Biotech AG Biotechnology Sector 2025 Annual Report
PRESS RELEASE published on 02/20/2026 at 07:00, 7 months 8 days ago Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization BB Biotech AG's Annual Report 2025 showcases strong performance and portfolio value realization. Shareholder returns, active capital management, and refined investment processes highlighted BB Biotech AG Portfolio Value Shareholder Returns Annual Report 2025 Investment Processes
BRIEF published on 01/23/2026 at 07:05, 8 months 5 days ago BB Biotech AG Reports Significant Profit for 2025 Investment Company BB Biotech AG Drug Developers 2025 Profit Share Price Development
BRIEF published on 01/23/2026 at 07:05, 8 months 5 days ago BB Biotech AG annonce des bénéfices importants pour 2025 BB Biotech AG Société D'investissement Développeurs De Médicaments Bénéfices 2025 Évolution Du Cours De L'action
BRIEF published on 01/23/2026 at 07:05, 8 months 5 days ago BB Biotech Reports Strong Preliminary 2025 Results and Dividend Proposal Dividend Proposal Share Performance BB Biotech Biotech Investment 2025 Financial Results
BRIEF published on 01/23/2026 at 07:05, 8 months 5 days ago BB Biotech annonce des résultats préliminaires solides pour 2025 et une proposition de dividende Proposition De Dividende BB Biotech Performance Des Actions Résultats Financiers 2025 Investissement En Biotechnologie
PRESS RELEASE published on 01/23/2026 at 07:00, 8 months 5 days ago EQS-Adhoc: BB Biotech AG closes the 2025 fiscal year with a profit BB Biotech AG closes the 2025 fiscal year with a profit of approximately CHF 578 million, reflecting share price development. Full report on Feb 20, 2026 BB Biotech AG Profit 2025 Fiscal Year Share Price Development CHF 578 Million
PRESS RELEASE published on 01/23/2026 at 07:00, 8 months 5 days ago BB Biotech: Preliminary full-year 2025 results and dividend proposal BB Biotech AG reports strong full-year 2025 results with +34.2% total return in CHF, +37.0% in EUR, and +53.7% in USD, proposes dividend of CHF 2.25 per share at AGM on March 19, 2026 Dividend Proposal Stock Market Full-year Results BB Biotech AG 2025 Performance
Published on 09/29/2026 at 00:00, 22 minutes ago Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
Published on 09/28/2026 at 23:00, 1 hour 22 minutes ago CORRECTION FROM SOURCE: Organto Foods Highlights Record First Half Results and Progress on Key Strategic Initiatives
Published on 09/28/2026 at 15:00, 9 hours 22 minutes ago Vox to Acquire Silver Royalty over the Sorby Hills Project in Australia
Published on 09/28/2026 at 14:45, 9 hours 37 minutes ago Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Published on 09/28/2026 at 14:30, 9 hours 52 minutes ago Drilling at Cat Creek Intersects a Copper-Molybdenum Porphyry System Visible Molybdenite-Chalcopyrite Over Significant Core Widths
Published on 09/28/2026 at 22:14, 2 hours 8 minutes ago EQS-Adhoc: Extension of the Managing Directors' employment contracts of Carsten Cramer, Lars Ricken and Thomas Treß – Carsten Cramer appointed Chairman of the Management Board
Published on 09/28/2026 at 19:24, 4 hours 57 minutes ago EQS-Adhoc: Hapag-Lloyd further raises its earnings outlook for the current financial year
Published on 09/28/2026 at 19:00, 5 hours 22 minutes ago PATRIMOINE ET COMMERCE : Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 21 septembre 2026 au 25 septembre 2026
Published on 09/28/2026 at 18:00, 6 hours 22 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 09/28/2026 (French only)
Published on 09/28/2026 at 18:00, 6 hours 22 minutes ago GEVELOT S.A.: Déclaration hebdomadaire de rachat d'actions 28/09/2026
Published on 09/28/2026 at 17:54, 6 hours 27 minutes ago Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Published on 09/28/2026 at 17:54, 6 hours 27 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 21 et le 25 septembre 2026
Published on 09/28/2026 at 17:45, 6 hours 37 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 09/28/2026 at 17:35, 6 hours 47 minutes ago Déclaration hebdomadaire d'opérations effectuées du 21 au 25 septembre 2026
